METTL3 and Alzheimer disease: Here, we investigate the relationship between m6A modification and AD pathology, and the therapeutic potential of modulating excessive m6A via its “writer” methyltransferase METTL3 in a humanized P301S tau transgenic mouse model of AD (PS19).